CLINICAL RESEARCH: CLINICAL TRIAL
Influence of Continuous Infusion of Low-Dose Human Atrial Natriuretic Peptide on Renal Function During Cardiac SurgeryA Randomized Controlled Study
Akira Sezai, MD, PhD*,*,
Mitsumasa Hata, MD, PhD*,
Tetsuya Niino, MD, PhD*,
Isamu Yoshitake, MD, PhD*,
Satoshi Unosawa, MD, PhD*,
Shinji Wakui, MD, PhD*,
Shunji Osaka, MD, PhD*,
Tadateru Takayama, MD, PhD ,
Yuji Kasamaki, MD, PhD,
Atsushi Hirayama, MD, PhD and
Kazutomo Minami, MD, PhD*
* Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan
Department of Cardiology, Nihon University School of Medicine, Tokyo, Japan
Manuscript received January 8, 2009;
revised manuscript received April 29, 2009,
accepted May 25, 2009.
* Reprint requests and correspondence: Dr. Akira Sezai, The Department of Cardiovascular Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi Itabashi-ku, Tokyo 173-8610, Japan (Email: asezai{at}med.nihon-u.ac.jp).
Objectives: The purpose of this study was to determine the effect of human atrial natriuretic peptide (hANP) in patients who underwent coronary artery bypass grafting (CABG) on renal function.
Background: Acute renal failure after cardiac surgery is associated with high morbidity and mortality.
Methods: A total of 504 patients who underwent CABG were divided into 2 groups: 1 group received hANP at 0.02 µg/kg/min from the start of cardiopulmonary bypass (hANP group), and 1 group did not receive hANP (placebo group). Various parameters were measured before and after surgery.
Results: There was no difference in mortality between the 2 groups, but post-operative complications were less frequent in the hANP group (p = 0.0208). In the hANP group, serum creatinine (Cr) was significantly lower and urinary Cr and Cr clearance were significantly higher from post-operative day 1 to week 1. The maximum post-operative Cr level and percent increase of Cr were significantly lower in the hANP group (p < 0.0001). Patients with Cr exceeding 2.0 mg/dl included 1 in the hANP group and 8 in the placebo group, showing a significant difference (p = 0.0374). Four patients in the placebo group and none in the hANP group required hemodialysis, but the difference was not statistically significant.
Conclusions: Continuous infusion of low-dose hANP from the start of cardiopulmonary bypass effectively maintained post-operative renal function. Infusion of hANP prevents early post-operative acute renal failure and helps to achieve safer cardiac surgery. (Clinical Trial registration number: UMIN000001440)
Key Words: human atrial natriuretic peptide • cardiopulmonary bypass • cardiac surgery • renal failure • coronary artery bypass grafting
|
Abbreviations and Acronyms
| % Cr = percent increase of creatinine | | BNP = brain natriuretic peptide | | CABG = coronary artery bypass grafting | | Ccr = creatinine clearance | | CH20
= free water clearance | | CPB = cardiopulmonary bypass | | Cr = creatinine | | FENa = fractional sodium excretion | | hANP = human atrial natriuretic peptide | | ICU = intensive care unit | | OPCAB = off-pump coronary artery bypass | | RAAS = renin-angiotensin-aldosterone system | | RFI = renal failure index |
|
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A22.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
T. Nojiri, K. Yamamoto, H. Maeda, Y. Takeuchi, Y. Funakoshi, M. Inoue, and M. Okumura
Effect of low-dose human atrial natriuretic peptide on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer: A double-blind, placebo-controlled study
J. Thorac. Cardiovasc. Surg.,
February 1, 2012;
143(2):
488 - 494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nojiri, M. Inoue, K. Yamamoto, H. Maeda, Y. Takeuchi, Y. Funakoshi, and M. Okumura
Effects of low-dose human atrial natriuretic peptide for preventing post-operative cardiopulmonary complications in elderly patients undergoing pulmonary resection for lung cancer
Eur J Cardiothorac Surg,
January 18, 2012;
(2012)
ezr202v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sezai, M. Hata, T. Niino, I. Yoshitake, S. Unosawa, S. Wakui, H. Kimura, M. Shiono, T. Takayama, and A. Hirayama
Results of Low-Dose Human Atrial Natriuretic Peptide Infusion in Nondialysis Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting: The NU-HIT (Nihon University Working Group Study of Low-Dose hANP Infusion Therapy During Cardiac Surgery) Trial for CKD
J. Am. Coll. Cardiol.,
August 23, 2011;
58(9):
897 - 903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Boerrigter and J. C. Burnett Jr
Natriuretic Peptides: Renal Protective After All?
J. Am. Coll. Cardiol.,
August 23, 2011;
58(9):
904 - 906.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sezai, K. Minami, T. Nakai, M. Hata, I. Yoshitake, S. Wakui, M. Shiono, and A. Hirayama
Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: New evidence from the PASCAL trial
J. Thorac. Cardiovasc. Surg.,
June 1, 2011;
141(6):
1478 - 1487.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Haase, P. Devarajan, A. Haase-Fielitz, R. Bellomo, D. N. Cruz, G. Wagener, C. D. Krawczeski, J. L. Koyner, P. Murray, M. Zappitelli, et al.
The Outcome of Neutrophil Gelatinase-Associated Lipocalin-Positive Subclinical Acute Kidney Injury: A Multicenter Pooled Analysis of Prospective Studies
J. Am. Coll. Cardiol.,
April 26, 2011;
57(17):
1752 - 1761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Givertz
Adenosine A1 Receptor Antagonists at a Fork in the Road
Circ Heart Fail,
November 1, 2009;
2(6):
519 - 522.
[Full Text]
[PDF]
|
|
|
|
